Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643711 | 0.89 | FFAR1 (0.61) | FFAR1FFAR4KEAP1 | |
| Apteniol A SCHEMBL16431559 | 0.88 | FFAR1 (0.89) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL18269510 | 0.86 | FFAR1 (0.72) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL31238464 | 0.85 | PARP10 (0.58) | FFAR1SRD5A2FFAR4PARP10PARP3 | |
| SCHEMBL3602690 | 0.83 | SRD5A2 (0.58) | FFAR1SRD5A2PARP10PARP3LMNA | |
| SCHEMBL2774842 | 0.82 | FFAR1 (1.00) | FFAR1SRD5A2FFAR4KEAP1 | |
| Phenyl Propionic Acid SCHEMBL31208555 | 0.81 | NPC1 (0.61) | FFAR1FFAR4LMNAKEAP1 | |
| SCHEMBL3424976 | 0.81 | FFAR1 (0.77) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL6001141 | 0.79 | SMN1; SMN2 (0.62) | FFAR1LMNAKEAP1 | |
| SCHEMBL5898799 | 0.78 | FFAR1 (0.72) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | KAROBIO AB (SE) | 2009-07-29 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | FFAR1 54/4885SRD5A2 26/4885FFAR4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.